Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Therapy-Related Myeloid Neoplasm
Explore 10 assets in Therapy-Related Myeloid Neoplasm →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
other_biological
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03096782CT.gov Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | — | Completed | — | — | — |
NCT02727803CT.gov Personalized NK Cell Therapy in CBT | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Therapy-Related Myeloid Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit (this asset) | M.D. Anderson Cancer Center | P2 | B · 56 |
| Fludarabine | National Cancer Institute (NCI) | P2 | B |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
| Busulfanum | M.D. Anderson Cancer Center | P2 | B |
| Rituximab | M.D. Anderson Cancer Center | P2 | B |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | B |
| Clofarabine | M.D. Anderson Cancer Center | P2 | B |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | B |
| Melphalan | M.D. Anderson Cancer Center | P2 | B |
+6 more in the Therapy-Related Myeloid Neoplasm cohort
Other indications for Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 75 |
| Plasma Cell Myeloma | — | P4 | BBB · 72 |
| Myeloproliferative Neoplasm | — | P2/3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Human T-Lymphocyte Immunoglobulin, Rabbit in Therapy-Related Myeloid Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-human-t-lymphocyte-immunoglobulin-rabbit-therapy-related-myeloid-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →